嵌合抗原受体t细胞治疗

CAR - t细胞疗法, a form of immunotherapy, targets 和 destroys blood cancer cells.

Immunotherapy helps patients fight different forms of cancer by enabling the immune system to both recognize 和 attack cancer.

皇冠hga025大学洛杉矶分校的医生在癌症免疫治疗方面走在了前列. 作为CAR - t细胞疗法的领导者, we pioneered these groundbreaking treatments 和 continue to make them more effective.

什么是CAR - t细胞疗法?

CAR - t细胞疗法激活人体的免疫系统来对抗癌症. This groundbreaking treatment is a type of immunotherapy called effector cell therapy or engineered cell therapy. 免疫疗法仍然相对较新, but it shows promise for adults 和 children for whom other treatments have stopped working.

t细胞是免疫系统的核心组成部分. 在CAR - t细胞疗法中，从患者血液中收集t细胞. 然后, 在实验室里, specialists modify the T-cells so they can recognize 和 attack certain blood cancers.

这些经过修饰的细胞随后会被送回患者体内. 如果治疗成功, the newly modified T-cells will help a person’s immune system kill off cancer cells, 使病情得到缓解.

CAR - t细胞疗法是如何起作用的?

T-cells (a type of white blood cell) are the central components of the immune system. 在CAR - t细胞疗法中，从患者血液中收集t细胞. 然后, 在实验室里, specialists modify the T-cells so they can recognize 和 attack certain blood cancers.

这些经过修饰的细胞随后会被送回患者体内. 如果治疗成功, the newly modified T-cells will help a person’s immune system kill off cancer cells, 只需要一次治疗就能使病情缓解.

在此之前、期间你能期待什么 & CAR - t细胞治疗后?

当你开始CAR - t细胞治疗时，记住你得到了很好的治疗. UCLA Health specialists have delivered more than 200 infusions of FDA-approved CAR - t细胞疗法 since 2018.

CAR - t细胞治疗前:

激活myUCLAhealth (MyChart) 账户
下载MyChart应用到你的智能手机上
Complete tasks assigned to you in myUCLAhealth (MyChart), including daily symptom tracker tasks
阅读教育材料
Meet with a social worker to discuss a plan for your care while receiving CAR - t细胞疗法, 包括当地的住宿和交通需求
Complete an Advanced Care Planning appointment with a nurse practitioner (adults only)
参加所有预约和筛查测试，为CAR - t细胞治疗做准备
确定至少一名照顾者
与您的医疗保健提供者一起审查并签署同意书
Identify alternative transportation for at least eight weeks after your CAR - t细胞疗法; you cannot drive or operate heavy machinery for at least eight weeks

Your health care provider will collect the T-cells from your body using a process called apheresis. 在apheresis, 一台机器把你的血液分成不同的部分, 目的是只去除t细胞. 剩余的血液会回到你的身体. 你的t细胞可以从你的手臂静脉或导管中收集, 哪个是在收集开始前放置的.

The T-cells are sent to a laboratory where they are modified to attack cancer cells. 新的t细胞被保存在实验室中生长和繁殖. Once enough have been made, they are frozen until they are ready to be sent to UCLA Health.

在CAR - t细胞治疗期间:

Lymphodepletion: You will undergo chemotherapy treatment to prepare your body for the infusion of the T-cells. 这种治疗通常在我们的门诊进行. You will have a catheter (also known as a central line) placed before lymphodepletion, which will allow your health care team easy access to give you medications 和 fluids. 如果需要，导管将放置至少28天或更长时间.
医院/诊所录取: Once the chemotherapy is complete, you will be admitted to the clinic or hospital. 你的护理团队会确定位置. 你的团队会检查CAR - t细胞输注的细节. 你将被你的团队密切监测至少7到14天. 在医院期间，你将受到严密监视. 您可能连接到连续心脏和/或脉搏血氧仪监测.
CAR - t细胞输注: Day 0 is the day of the infusion of the CAR T-cells 和 is used as a starting point for counting how far out you are from receiving them. For example, the day after the infusion would be Day 1, the next Day 2, 和 so on.

CAR - t细胞治疗后:

After infusion, the T-cells will continue to multiply to target 和 attack your cancer cells. 你的安全是我们的首要任务. 一旦你接受了注射, your care team will monitor you closely for possible side effects 和 provide treatment if needed.

患者教育资源:

下面的指南提供了CAR - t细胞治疗患者的信息, 照顾者和家庭, 包括病人清单, 照顾者期望清单, 和 information on potential side effects of CAR - t细胞疗法和 details on the recovery process. 该指南以电子版和可下载的PDF格式呈现, 有英文和西班牙文两种版本.

CAR - t细胞疗法

英语翻书 |英语 PDF
西班牙语翻书 |西班牙 PDF

CAR - t细胞疗法的副作用

细胞因子释放综合征: 在一些病人中, substances called cytokines are released by the body in response to an overactive immune system. 病人可能会发高烧或发冷, 头痛, 恶心想吐, 呕吐, 腹泻, 头晕, 低血压, 呼吸困难或意识混乱.

神经系统: In rare cases after CAR T-cell infusion, the brain 和 neurologic system are temporarily altered. 患者可能会感到困惑, 说话困难或记忆力减退, 头痛, 癫痫发作, 震颤或失去知觉.

注意:大多数CAR - t细胞疗法的副作用是暂时的和可逆的.

谁是CAR - t细胞治疗的候选者?

FDA目前已经批准了6种CAR - t细胞疗法来治疗血癌. 它提供给有以下情况的患者:

癌症类型	病人的标准	处理类型*
弥漫大b细胞淋巴瘤(DLBCL)	复发或对既往治疗无效的成年患者.	Breyanzi(异cabtagene maraleucel) Kymriah (tisagenlecleucel) 叶卡塔(叶卡塔基)
急性淋巴细胞白血病(ALL)	Children 和 young adults up to age 25 who have relapsed or not responded to previous treatments.	Kymriah (tisagenlecleucel)
急性淋巴细胞白血病(ALL)	复发或对既往治疗无效的成年患者.	Tecartus(三羧基乙醇)
套细胞淋巴瘤(MCL)	复发或对既往治疗无效的成年患者.	Tecartus(三羧基乙醇)
滤泡性淋巴瘤(FL)	复发或对既往治疗无效的成年患者.	Yescarta (axicabtagene ciloledel)
多发性骨髓瘤(MM)	复发或对既往治疗无效的成年患者.	Abecma(二苯甲酰胺) Carvykti (ciltacabtagene autoeucel)

*你的医生会帮你确定最适合你的CAR - t细胞疗法.

为什么选择UCLA健康中心进行CAR - t细胞治疗?

Immunotherapy helps patients fight different forms of cancer by enabling the immune system to both recognize 和 attack cancer. 一种免疫疗法, 嵌合抗原受体t细胞疗法, 专门针对血癌，这样就能消灭它们.

The physicians 和 researchers at UCLA Health are at the forefront of immunotherapy innovation. 我们课程的亮点包括:

突破性的解决方案: In 2018, UCLA Health became one of the first health systems in the nation to offer commercial CAR - t细胞疗法. 2020年，皇冠hga025大学洛杉矶分校健康中心是首批提供食品的机构之一 & Drug Administration (FDA)-approved CAR - t细胞疗法 to treat relapsed or refractory mantle cell lymphoma. 我们之前在临床试验中为参与者提供了这种疗法.
经验和专业知识: 我们的优秀团队包括血液学专家, 肿瘤学, 以及血液和骨髓移植. 使用协调的方法, we work closely with experienced researchers to deliver groundbreaking cancer treatments through immunotherapy clinical trials 和 treatments.
临床试验: The physicians 和 researchers at the UCLA Health 约翰逊综合癌症中心 (JCCC) lead the way in cancer research. If you're eligible, you'll have access to a variety of immunotherapy clinical trials. Your doctor will discuss open CAR - t细胞疗法 trials currently available 和 help you assess the risks 和 benefits of treatment. 找一个临床试验.
开创最新疗法: UCLA Health specialists are consistently prepared to deliver new treatments as soon as they're approved by the FDA. We stay on top of the latest developments so we can offer effective treatments the moment they're available.